Imperial College London
Portrait Picture

Professor Thomas N Williams

Faculty of Medicine, Department of Surgery & Cancer

Chair in Haemoglobinopathy Research
 
 
 
//

Contact

 

tom.williams Website

 
 
//

Location

 

Norfolk PlaceSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Kapulu:2022:10.1186/s12879-022-07044-8,
author = {Kapulu, MC and Kimani, D and Njuguna, P and Hamaluba, M and Otieno, E and Kimathi, R and Tuju, J and Sim, BKL and CHMI-SIKA, Study Team},
doi = {10.1186/s12879-022-07044-8},
journal = {BMC Infect Dis},
title = {Controlled human malaria infection (CHMI) outcomes in Kenyan adults is associated with prior history of malaria exposure and anti-schizont antibody response},
url = {http://dx.doi.org/10.1186/s12879-022-07044-8},
volume = {22},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: Individuals living in endemic areas acquire immunity to malaria following repeated parasite exposure. We sought to assess the controlled human malaria infection (CHMI) model as a means of studying naturally acquired immunity in Kenyan adults with varying malaria exposure. METHODS: We analysed data from 142 Kenyan adults from three locations representing distinct areas of malaria endemicity (Ahero, Kilifi North and Kilifi South) enrolled in a CHMI study with Plasmodium falciparum sporozoites NF54 strain (Sanaria® PfSPZ Challenge). To identify the in vivo outcomes that most closely reflected naturally acquired immunity, parameters based on qPCR measurements were compared with anti-schizont antibody levels and residence as proxy markers of naturally acquired immunity. RESULTS: Time to endpoint correlated more closely with anti-schizont antibodies and location of residence than other parasite parameters such as growth rate or mean parasite density. Compared to observational field-based studies in children where 0.8% of the variability in malaria outcome was observed to be explained by anti-schizont antibodies, in the CHMI model the dichotomized anti-schizont antibodies explained 17% of the variability. CONCLUSIONS: The CHMI model is highly effective in studying markers of naturally acquired immunity to malaria. Trial registration Clinicaltrials.gov number NCT02739763. Registered 15 April 2016.
AU  - Kapulu,MC
AU  - Kimani,D
AU  - Njuguna,P
AU  - Hamaluba,M
AU  - Otieno,E
AU  - Kimathi,R
AU  - Tuju,J
AU  - Sim,BKL
AU  - CHMI-SIKA,Study Team
DO  - 10.1186/s12879-022-07044-8
PY  - 2022///
TI  - Controlled human malaria infection (CHMI) outcomes in Kenyan adults is associated with prior history of malaria exposure and anti-schizont antibody response
T2  - BMC Infect Dis
UR  - http://dx.doi.org/10.1186/s12879-022-07044-8
UR  - https://www.ncbi.nlm.nih.gov/pubmed/35073864
UR  - http://hdl.handle.net/10044/1/95382
VL  - 22
ER  -
Download